Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods

Jason G. Glanzer, Shengqin Liu, Gregory G Oakley

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The pharmacological suppression of the DNA damage response and DNA repair can increase the therapeutic indices of conventional chemotherapeutics. Replication Protein A (RPA), the major single-stranded DNA binding protein in eukaryotes, is required for DNA replication, DNA repair, DNA recombination, and DNA damage response signaling. Through the use of high-throughput screening of 1500 compounds, we have identified a small molecule inhibitor, 15-carboxy-13-isopropylatis-13-ene-17,18-dioic acid (NSC15520), that inhibited both the binding of Rad9-GST and p53-GST fusion proteins to the RPA N-terminal DNA binding domain (DBD), interactions that are essential for robust DNA damage signaling. NSC15520 competitively inhibited the binding of p53-GST peptide with an IC50 of 10 μM. NSC15520 also inhibited helix destabilization of a duplex DNA (dsDNA) oligonucleotide, an activity dependent on the N-terminal domain of RPA70. NSC15520 did not inhibit RPA from binding single-stranded oligonucleotides, suggesting that the action of this inhibitor is specific for the N-terminal DBD of RPA, and does not bind to DBDs essential for single-strand DNA binding. Computer modeling implicates direct competition between NSC15520 and Rad9 for the same binding surface on RPA. Inhibitors of protein-protein interactions within the N-terminus of RPA are predicted to act synergistically with DNA damaging agents and inhibitors of DNA repair. Novel compounds such as NSC15520 have the potential to serve as chemosensitizing agents.

Original languageEnglish (US)
Pages (from-to)2589-2595
Number of pages7
JournalBioorganic and Medicinal Chemistry
Volume19
Issue number8
DOIs
StatePublished - Apr 15 2011

Fingerprint

Replication Protein A
Protein Interaction Domains and Motifs
Computer Simulation
Molecules
Repair
Oligonucleotides
Recombinational DNA Repair
Proteins
Eukaryota
Protein Binding
Inhibitory Concentration 50
In Vitro Techniques
Carrier Proteins
Screening
Fusion reactions
Throughput
Pharmacology
Peptides
Acids
DNA

Keywords

  • Docking
  • EMSA
  • High-throughput screen
  • Inhibitors
  • Replication Protein A

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods. / Glanzer, Jason G.; Liu, Shengqin; Oakley, Gregory G.

In: Bioorganic and Medicinal Chemistry, Vol. 19, No. 8, 15.04.2011, p. 2589-2595.

Research output: Contribution to journalArticle

@article{db99cce04dec4c139d8f3745d717e27c,
title = "Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods",
abstract = "The pharmacological suppression of the DNA damage response and DNA repair can increase the therapeutic indices of conventional chemotherapeutics. Replication Protein A (RPA), the major single-stranded DNA binding protein in eukaryotes, is required for DNA replication, DNA repair, DNA recombination, and DNA damage response signaling. Through the use of high-throughput screening of 1500 compounds, we have identified a small molecule inhibitor, 15-carboxy-13-isopropylatis-13-ene-17,18-dioic acid (NSC15520), that inhibited both the binding of Rad9-GST and p53-GST fusion proteins to the RPA N-terminal DNA binding domain (DBD), interactions that are essential for robust DNA damage signaling. NSC15520 competitively inhibited the binding of p53-GST peptide with an IC50 of 10 μM. NSC15520 also inhibited helix destabilization of a duplex DNA (dsDNA) oligonucleotide, an activity dependent on the N-terminal domain of RPA70. NSC15520 did not inhibit RPA from binding single-stranded oligonucleotides, suggesting that the action of this inhibitor is specific for the N-terminal DBD of RPA, and does not bind to DBDs essential for single-strand DNA binding. Computer modeling implicates direct competition between NSC15520 and Rad9 for the same binding surface on RPA. Inhibitors of protein-protein interactions within the N-terminus of RPA are predicted to act synergistically with DNA damaging agents and inhibitors of DNA repair. Novel compounds such as NSC15520 have the potential to serve as chemosensitizing agents.",
keywords = "Docking, EMSA, High-throughput screen, Inhibitors, Replication Protein A",
author = "Glanzer, {Jason G.} and Shengqin Liu and Oakley, {Gregory G}",
year = "2011",
month = "4",
day = "15",
doi = "10.1016/j.bmc.2011.03.012",
language = "English (US)",
volume = "19",
pages = "2589--2595",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods

AU - Glanzer, Jason G.

AU - Liu, Shengqin

AU - Oakley, Gregory G

PY - 2011/4/15

Y1 - 2011/4/15

N2 - The pharmacological suppression of the DNA damage response and DNA repair can increase the therapeutic indices of conventional chemotherapeutics. Replication Protein A (RPA), the major single-stranded DNA binding protein in eukaryotes, is required for DNA replication, DNA repair, DNA recombination, and DNA damage response signaling. Through the use of high-throughput screening of 1500 compounds, we have identified a small molecule inhibitor, 15-carboxy-13-isopropylatis-13-ene-17,18-dioic acid (NSC15520), that inhibited both the binding of Rad9-GST and p53-GST fusion proteins to the RPA N-terminal DNA binding domain (DBD), interactions that are essential for robust DNA damage signaling. NSC15520 competitively inhibited the binding of p53-GST peptide with an IC50 of 10 μM. NSC15520 also inhibited helix destabilization of a duplex DNA (dsDNA) oligonucleotide, an activity dependent on the N-terminal domain of RPA70. NSC15520 did not inhibit RPA from binding single-stranded oligonucleotides, suggesting that the action of this inhibitor is specific for the N-terminal DBD of RPA, and does not bind to DBDs essential for single-strand DNA binding. Computer modeling implicates direct competition between NSC15520 and Rad9 for the same binding surface on RPA. Inhibitors of protein-protein interactions within the N-terminus of RPA are predicted to act synergistically with DNA damaging agents and inhibitors of DNA repair. Novel compounds such as NSC15520 have the potential to serve as chemosensitizing agents.

AB - The pharmacological suppression of the DNA damage response and DNA repair can increase the therapeutic indices of conventional chemotherapeutics. Replication Protein A (RPA), the major single-stranded DNA binding protein in eukaryotes, is required for DNA replication, DNA repair, DNA recombination, and DNA damage response signaling. Through the use of high-throughput screening of 1500 compounds, we have identified a small molecule inhibitor, 15-carboxy-13-isopropylatis-13-ene-17,18-dioic acid (NSC15520), that inhibited both the binding of Rad9-GST and p53-GST fusion proteins to the RPA N-terminal DNA binding domain (DBD), interactions that are essential for robust DNA damage signaling. NSC15520 competitively inhibited the binding of p53-GST peptide with an IC50 of 10 μM. NSC15520 also inhibited helix destabilization of a duplex DNA (dsDNA) oligonucleotide, an activity dependent on the N-terminal domain of RPA70. NSC15520 did not inhibit RPA from binding single-stranded oligonucleotides, suggesting that the action of this inhibitor is specific for the N-terminal DBD of RPA, and does not bind to DBDs essential for single-strand DNA binding. Computer modeling implicates direct competition between NSC15520 and Rad9 for the same binding surface on RPA. Inhibitors of protein-protein interactions within the N-terminus of RPA are predicted to act synergistically with DNA damaging agents and inhibitors of DNA repair. Novel compounds such as NSC15520 have the potential to serve as chemosensitizing agents.

KW - Docking

KW - EMSA

KW - High-throughput screen

KW - Inhibitors

KW - Replication Protein A

UR - http://www.scopus.com/inward/record.url?scp=79954423814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954423814&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2011.03.012

DO - 10.1016/j.bmc.2011.03.012

M3 - Article

C2 - 21459001

AN - SCOPUS:79954423814

VL - 19

SP - 2589

EP - 2595

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 8

ER -